Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07282158

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

This clinical trial tests an adapted version of the Helping Ovarian Cancer Patients Cope (HOPE) intervention to address burnout among gynecologic oncology clinicians. Stress and burnout among gynecologic oncology clinicians can have far-reaching impacts not only on physicians at the individual level (e.g., distress, mental illness) but also at the professional (e.g., worse patient outcomes, increased errors) and societal levels (fewer physicians in this specialty, more system strain). The original Helping Ovarian Cancer Patients Cope (HOPE) is a workshop to promote hope among patients with ovarian cancer through creating positive narratives using the hope theory and social-cognitive theory. The adapted intervention for clinicals (HOPE-C) will use the same concepts but tailored to clinician experiences by fostering peer support and retelling their challenging stories and may address burnout for gynecologic oncology clinicians.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Carcinoma Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Mental Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Psychiatric Disorder Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location status: Recruiting

Location contact

Megan J. Shen, PhD

CONTACT

[email protected]

206-667-4172

Megan J. Shen, PhD

PRINCIPAL_INVESTIGATOR

About this study

OUTLINE:

OBJECTIVE 1 DEVELOPMENT OF INTERVENTION: Clinicians review HOPE-C intervention materials and complete an interview and questionnaire on study.

OBJECTIVE 2 PILOT TRIAL: Clinicians attend HOPE-C sessions (changing their narrative, managing life's uncertainty and finding meaning) once weekly for 4 weeks, with each session lasting approximately 30-45 minutes. Clinicians complete a questionnaire before and after completing all HOPE-C sessions.

OBJECTIVE 3: Clinicians may undergo an interview after completing HOPE-C sessions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years of age or older
  • English speaking
  • Able to provide informed consent
  • Working with patients with ovarian cancer (gynecologic oncologists, medical oncologists, nurses, social workers, and advance practice providers [APPs])

Treatment and study plan

behavioral intervention

Behavioral

Complete HOPE-C sessions

Other names: Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments, Behavioural

interview

Other

Complete interview

Survey Administration

Other

Ancillary studies

Primary outcomes

  1. Objective 1: Clinician feedback for Helping Ovarian Cancer Patients Cope-Clinician Burnout (HOPE-C)

    Time frame: Day 1

    Will assess clinician's feedback around the content, delivery structure, and materials for the adapted HOPE-C intervention. Qualitative Description will be used to analyze the data.

  2. Objective 2: Feasibility (Accrual rate)

    Time frame: At time of enrollment

    Feasibility cutoff includes ≥ 50% of eligible clinicians enrolling in the study.

  3. Objective 2: Feasibility (Rate of intervention completion)

    Time frame: At 4 weeks

    Feasibility cutoff includes ≥ 50% of enrolled clinicians completing all sessions.

  4. Objective 2: Feasibility (Rate of survey completion)

    Time frame: At baseline and 2-week post-intervention

    Feasibility cutoff includes ≥ 50% of enrolled clinicians completing all surveys.

  5. Objective 2: Acceptability of HOPE-C

    Time frame: At 2-week post-intervention

    Assessed by the Theoretical Framework of Acceptability (TFA) questionnaire, which is an 8-item questionnaire assessing acceptability of healthcare interventions across seven constructions: Affective Attitude, Burden, Ethicality, Intervention Coherence, Opportunity Costs, Perceived Effectiveness and Self-efficacy. Items are rated on a 5-point Likert scale (e.g., 1 = strongly dislike, 5 = strongly like) and a mean is computed across all seven constructs (n=7 items) and a single outcome is examined for the general item. Total mean score ranges from 1 to 5, with higher scores indicating greater acceptability of the intervention.

  6. Objective 2: Satisfaction of HOPE-C

    Time frame: At 2-week post-intervention

    Will be assessed by using three items assessing overall satisfaction. A cutoff score of ≥ 7 (out of 10) will be used for each satisfaction item.

  7. Objective 3: Optimization of the intervention

    Time frame: At 2-week post-intervention

    Feedback will be gathered from clinicians who participated in the intervention to assess their feedback on how to optimize the intervention in clinical settings.

  8. Objective 3: Delivery of the intervention

    Time frame: At 2-week post-intervention

    Feedback will be gathered from clinicians who participated in the intervention to assess their feedback on the delivery of the intervention in clinical settings.

Study contacts

Contact information is provided by the study sponsor or research team.

Megan J. Shen, PhD

CONTACT

[email protected]

206-667-4172

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Collaborators

  • Andy Hill CARE Fund

Registry information

Official study title

Adaptation of Helping Ovarian Cancer Patients Cope (HOPE) for Clinician Burnout (HOPE-C)

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Dec 15, 2025
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.